NCT07161687

A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

HYMPAVZI S.C. INJECTION 150 mg Pen SPECIAL INVESTIGATION

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.

Detailed description

The objective of this study is to assess the safety of this drug under actual usage conditions in patients with congenital hemophilia who do not have inhibitors. The observation period will be up to three years. However, for cases in which administration of the drug is discontinued, information will be collected up to the point of discontinuation.

Conditions

• Hemophilia A or B

Interventions

Type	Name	Description
DRUG	Marstacimab	For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcutaneously at a dose of 300 mg as the initial dose, followed by 150 mg once weekly. If the patient weighs 50 kg or more and shows an inadequate response, the dose may be increased to 300 mg once weekly for subcutaneous administration.

Timeline

• Start date: 2025-10-30
• Primary completion: 2030-04-11
• Completion: 2030-04-11
• First posted: 2025-09-09
• Last updated: 2026-03-30

Locations

1 site across 1 country: Japan